Today: 14 June 2026

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics shares jumped nearly 30% and traded around $2 after last week’s $78 million takeover deal with XenoTherapeutics. The offer includes about $1.82 per share in cash plus a non-transferable contingent value right tied to future asset sales and milestones. The transaction is expected to close in Q1 2026, pending shareholder and court approval in Québec.
17 November 2025
·
Elbit Systems (ESLT) Jumps on $2.3 Billion Contract Win as Q3 Earnings Loom – 17 November 2025 Update

Elbit Systems (ESLT) Jumps on $2.3 Billion Contract Win as Q3 Earnings Loom – 17 November 2025 Update

Elbit Systems announced a $2.3 billion international defense contract to be delivered over eight years, with the customer and systems undisclosed. The news sent ESLT shares sharply higher on both the Nasdaq and TASE. The deal was confirmed in a press release and SEC filing one day before Elbit’s Q3 2025 earnings report.
17 November 2025
···
Sociedad Química y Minera (SQM) Soars as Lithium Rebounds and Codelco JV Gets Final Green Light

Sociedad Química y Minera (SQM) Soars as Lithium Rebounds and Codelco JV Gets Final Green Light

SQM shares surged about 12% Monday in New York, hitting a 52-week high near $61 after China approved its lithium joint venture with Codelco. Major funds including Itaú Unibanco and KBC Group disclosed new or larger stakes. Lithium prices rose on signs of stronger Chinese demand. Investors await SQM’s Q3 2025 earnings report due Tuesday.
17 November 2025
···
PACS Group (PACS) Stock Soars as Company Pledges to Clear SEC Filing Backlog by November 19, 2025

PACS Group (PACS) Stock Soars as Company Pledges to Clear SEC Filing Backlog by November 19, 2025

PACS Group shares surged nearly 50% to $15.90 Monday after the company said it will file all overdue SEC reports and release Q3 2025 earnings on November 19. The filings aim to resolve delisting and default risks tied to a months-long reporting backlog. PACS confirmed a $61–65 million overstatement in 2024 Medicare Part B revenue, citing an ongoing audit probe. Trading volume topped 4.3 million shares by late morning.
17 November 2025
·
ZIM Integrated Shipping (NYSE: ZIM) Jumps Toward $17 as Bulltick Boosts Stake Ahead of Q3 Earnings – November 17, 2025

ZIM Integrated Shipping (NYSE: ZIM) Jumps Toward $17 as Bulltick Boosts Stake Ahead of Q3 Earnings – November 17, 2025

ZIM shares jumped about 6% to $17 late morning Monday as traders positioned ahead of Thursday’s Q3 earnings report. Bulltick Wealth Management increased its stake by 33% to 88,000 shares. Options markets priced in an 11–12% move post-earnings, signaling volatility. Today is also the record date for ZIM’s December 19 shareholder meeting in Haifa.
17 November 2025
··
Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer launched Rimegepant ODT, a migraine tablet, in India, targeting a $200 million market. Shares traded near $25.28, down 55% from late 2022, with a dividend yield around 7%. Analysts maintain a “Hold” rating and see limited short-term movement. The new product addresses migraine in adults unresponsive to standard treatments.
17 November 2025
··
GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

GameStop shares traded around $20.70 late Monday morning, up slightly after hitting a new 52-week low of $18.89 last week. The stock remains down 34% year-to-date despite recent profitable quarters and a viral “Trade Anything Day” promotion. Short interest is near a 12-month high, fueling debate among retail traders over valuation and short-squeeze potential.
17 November 2025
·
Social Security COLA 2026 and the $200 Boost Bill: How Much Your Check Could Really Rise (Update for November 17, 2025)

Social Security COLA 2026 and the $200 Boost Bill: How Much Your Check Could Really Rise (Update for November 17, 2025)

Social Security and SSI benefits will rise 2.8% in 2026, increasing the average retired worker’s monthly check by about $56. The taxable wage cap moves to $184,500, and the maximum benefit at full retirement age reaches $4,152 per month. Medicare Part B premiums will rise to $202.90. A Senate bill proposing a $200 monthly boost for six months in 2026 remains at the introduction stage.
17 November 2025
Rivian Stock (RIVN) Today: Price Targets Raised, Battery Bug Emerges and Big Holders Trim Stakes – November 17, 2025

Rivian Stock (RIVN) Today: Price Targets Raised, Battery Bug Emerges and Big Holders Trim Stakes – November 17, 2025

Rivian shares traded near $15.06 early afternoon November 17, down 0.3% after a surge of over 30% post-Q3 earnings. The company reported its first positive gross profit, while Stifel and Tigress Financial raised price targets. Headlines flagged a battery calibration bug in R1 models, and filings showed major investors and CEO RJ Scaringe selling shares. Volume topped 14 million.
17 November 2025
··
Tesla (TSLA) News Today: China Supply Chain Shake-Up, Thiel Trims Stake, AI5 Delay and Divided Wall Street – 17 November 2025

Tesla (TSLA) News Today: China Supply Chain Shake-Up, Thiel Trims Stake, AI5 Delay and Divided Wall Street – 17 November 2025

Tesla shares rose about 2.5% to $414.46 on November 17 after Elon Musk ordered U.S. suppliers to phase out China-made parts within two years. Peter Thiel cut his Tesla stake by over 75% in Q3. Musk said the next-gen AI5 chip is delayed until mid-2027. Wall Street remains split on robotaxi prospects, with price targets ranging from $131 to $509.
17 November 2025
··
Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford shares have surged about 32–37% in 2025, outpacing the S&P 500 and trading near a 52-week high around $13.20. Wall Street cites Ford’s shift away from costly EV projects toward profitable trucks and hybrids, despite ongoing multi-billion-dollar EV losses. Analyst targets average $11.73, with most maintaining a “Hold” rating. The stock’s dividend yield remains near 4.5%.
17 November 2025
···
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor Technologies shares traded at $8.03 on November 17, down 1% after recent highs above $10. The company’s controversial warrant dividend, set for distribution on November 21, targets short sellers and has fueled volatility. Morgan Stanley maintained a Hold rating, while quants noted large hedge fund flows. Opendoor stock remains up several hundred percent year-to-date.
17 November 2025
··
Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings secured an $8.2 million contract to deploy counter-drone systems at a major European airport and closed its $225 million acquisition of Israel-based Sentrycs. The company reported record Q3 revenue of $10.1 million, up more than sixfold year-over-year. ONDS shares traded around $7.00 midday, down 2.5% after recent gains. Analyst price targets rose, with Oppenheimer upgrading the stock to “outperform.”
17 November 2025
··
Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat shares traded near $1.08 Monday after law firm Bleichmar Fonti & Auld LLP announced a new securities-fraud investigation into the company. The probe centers on whether Beyond Meat misled investors about asset values and impairment charges. Short interest has dropped to 13.2%, its lowest since early 2021. The stock remains down about 70% for the year.
17 November 2025
·
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical reported 20–30-point gains in quality-of-life scores at three months in a subgroup analysis from its PoC 1 study for severe pancreatic cancer pain. Even Stage 4 patients saw durable symptom and function improvements after nerve ablation. AMIX shares nearly doubled intraday on heavy volume, ranking among Nasdaq’s top gainers. The company remains pre-revenue and highly volatile.
17 November 2025
··
1 … 28 29 30 31 32 … 146

Stock Market Today

  • Copa Holdings (CPA) Stock: Mixed Valuation Signals After Strong Returns
    June 14, 2026, 1:50 AM EDT. Copa Holdings (NYSE:CPA) has delivered strong recent returns, with a 1-year total shareholder return of 43.62% and 3-month gains of 24.27%. The stock trades at $141.69, showing a 7.57% gain over the last month. Analysts highlight a potential 14.2% undervaluation with a fair value estimate of $165.13, supported by revenue growth, disciplined cost management, and efficient Boeing 737 MAX fleet deployment. However, a discounted cash flow (DCF) valuation suggests the stock may be overvalued at $128.17, raising valuation questions. Key risks include potential spikes in fuel costs and pricing pressure in Latin American markets. Investors face a choice between differing valuation models amid firm momentum and competitive challenges.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop